Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5562 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 8 9 10 ... 54 55 56  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
European Pharma Oligonucleotide Consortium–Pfizer: oligonucleotide drugs, 2018– collab Pfizer is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–Roche: oligonucleotide drugs, 2018– collab Roche is founding member of EPOC 2018-01-01
European Pharma Oligonucleotide Consortium–Sanofi: oligonucleotide drugs, 2018– collab Sanofi is founding member of EPOC 2018-01-01
Siemens–OTHER: investment, 2018H1 PLANNED listing of newSiemens Healthineers AG at Frankfurt Stock Exchange 2018-01-01
BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US 2017-12-21
Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share 2017-12-21
Roche–Idorsia: cancer immunotherapy, 201712– collab research + excl license option €15m upfront + €445m milestones plus sales milestones + royalties 2017-12-20
Boehringer–Autifony: CNS drugs, 201712– collab €25m upfront + up to total of €627.5m excl option to acquire KV3.1/3.2 positive modulators for BI 2017-12-18
Danaher–Cotecna: mass spectrometry, –201712 collab developm LC-MS/MS method for pesticide detection by Sciex + NofaLab 2017-12-18
Roche–Horizon Discovery: reference standards, 201712– collab developm + supply of FFPE reference standards for ICH-NTRK assays for Roche Dx 2017-12-18
Fast Track Diagnostics–Siemens: investment, 201712 acquisiton €na of FTD by Siemens Healthineers 2017-12-15
Evotec–TU Dresden: drug discovery, 201712– collab research €na small-molecule candidates for retinal diseases using iPSC technology with CRTD 2017-12-13
Flexion Therapeutics–GeneQuine: gene therapy, 201712 acquisition $2m upfront + $62.7m milestones + royalties ww rights to GQ-203 by Flexion 2017-12-13
NorthSea Therapeutics–BASF: icosabutate, 201712– license from Pronova BioPharma Norge AS 2017-12-12
NorthSea Therapeutics–SEVERAL: investment, 201712 financing round Series A €25m co-led by Forbion + BGV + incl Novo Seeds + New Science Ventures 2017-12-12
Oncgnostics–SEVERAL: investment, 201712–201801 crowdfunding campaign €750k via Seedmatch platform 2017-12-12
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF 2017-12-11
Aelin Therapeutics–Boehringer: investment, 201712 financing round Series A totalling €27m incl investor BIVF 2017-12-11
Aelin Therapeutics–Flanders (govt): investment, 201712 financing round Series A totalling €27m incl investor PMV 2017-12-11
Aelin Therapeutics–Fund+: investment, 201712 financing round Series A totalling €27m incl investor Fund+ 2017-12-11
Aelin Therapeutics–Life Sciences Partners: investment, 201712 financing round Series A totalling €27m incl lead investor LSP 2017-12-11
Aelin Therapeutics–Novartis: investment, 201712 financing round Series A totalling €27m incl investor Novartis Venture Fund 2017-12-11
Aelin Therapeutics–SEVERAL: investment, 201712 financing round Series A €27m from LSP + PMV + Novartis Venture Fund + BIVF + Fund+ 2017-12-11
Boehringer–AbeXXa Biologics: drug target research, 201712 collab existent to identify molecular protein targets for cancer 2017-12-11
Boehringer–Univ California: cancer vaccine, 201712 collab existent to develop vaccine technology platform with UCLA 2017-12-11
Hookipa–BioMedPartners: investment, 201712 financing round Series C totalling €50m incl returning investor BioMedPartners 2017-12-11
Hookipa–Boehringer: investment, 201712 financing round Series C totalling €50m incl returning investor BIVF 2017-12-11
Hookipa–Forbion: investment, 201712 financing round Series C totalling €50m incl returning investor Forbion Capital Partners 2017-12-11
Hookipa–Gilead: investment, 201712 financing round Series C totalling €50m incl new + strategic investor Gilead 2017-12-11
Hookipa–HBM: investment, 201712 financing round Series C totalling €50m incl new investor HBM Partners 2017-12-11
Hookipa–Hillhouse Capital: investment, 201712 financing round Series C totalling €50m incl new investor Hillhouse Capital 2017-12-11
Hookipa–OTHER: investment, 201712 financing round Series C totalling €50m incl undisclosed US public investment fund as new + lead investor 2017-12-11
Hookipa–SEVERAL: investment, 201712 financing round Series C €50m led by undisclosed US public investment fund 2017-12-11
Hookipa–Sirona Capital: investment, 201712 financing round Series C totalling €50m incl new investor Sirona Capital 2017-12-11
Hookipa–Sofinnova: investment, 201712 financing round Series C totalling €50m incl returning investor Sofinnova Partners 2017-12-11
Hookipa–Takeda: investment, 201712 financing round Series C totalling €50m incl returning investor Takeda Ventures 2017-12-11
thinXXS Microtechnology–Idex Corporation: investment, 201712 acquisition of thinXXS Microtechnology AG by Idex Corp 2017-12-11
PGS.Holland–bio.logis: genetic software, 201712– distribution of bio.logis GIMS in Benelux + Scandinavia + UK by PGS.Holland BV 2017-12-08
Cell Medica–Coulter Partners: recruitment services, 201712 supply service placement of Annalisa Jenkins as new Board Chair of Cell Medica 2017-12-07
Hepa Wash–Germany (govt): business development, 201712– supply service support in US with German Accelerator Life Sciences programme 2017-12-07
Charles River–ERS Genomics: CRISPR technology, 201712– license €na ww non-excl for CRISPR-Cas9 technology to generate modified cell lines 2017-12-06
Horizon Discovery–ERS Genomics: CRISPR technology, 201712– license ww non-excl expansion 2017-12-05
Novartis–Medigene: Veregen, 201712– acquisition €na of US rights to Veregen by Fougera Pharmaceuticals Inc 2017-12-05
Probiodrug–Crossbeta Biosciences: biomarker research, 201712– collab extension developm Alzheimer biomarker to support Probiodrug’s clinical program 2017-12-05
Probiodrug–MC Services: public relations, 201712 service existent by MC Services 2017-12-05
Probiodrug–Optimum Strategic Communications: public relations, 201712 service existent by Optimum 2017-12-05
Probiodrug–Trout Group: public relations, 201712 service existent by The Trout Group 2017-12-05
Arrowhead–Silence Therapeutics: investment, 201712 DIVESTMENT 2.036m common shares for $7.5m w realised profit of $4.1m 2017-12-04
Evotec–Ncardia: drug discovery technology, 201712– license ww non-excl €na to access iPSC-derived disease models of Ncardia 2017-12-04
JnJ–Idorsia: aprocitentan, 201712– collab developm + license ww commerc for Janssen $230m upfront + royalties 20–35% 2017-12-04
Anaveon–Basel (govt): investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch 2017-12-01
Anaveon–SEVERAL: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch 2017-12-01
Anaveon–Univ Zurich: investment, 201712 seed funding round from UZH Life Sciences Fund + BaseLaunch 2017-12-01
Roche–Confo Therapeutics: drug discovery services, 201712–202005 collab up to €87.5m plus milestones r+d + commerc small molecule GPCR agonists 2017-12-01
I-Mab–MorphoSys: antibody cancer drug, 201711– license excl Greater China for MOR202 with $20m upfront + $100m milestones + tiered 2-digit royalties 2017-11-30
Enyo Pharma–Charles River: drug discovery services, –201711 collab drug target identification of EYP002 using CCMS technology 2017-11-28
Bitkom–Bayer: digital economy, 201711 Bayer is member of Bitkom w particular focus on digital health + digital farming 2017-11-27
Boehringer–BioMed X: pharma research, 201711– collab new BioMed X research group in bacterial modulation of innate immunity 2017-11-27
Geneva Biotech–Sphere Fluidics: genomic technology, 201711– collab to develop large DNA cargo gene deliver + genome engineering systems 2017-11-27
LIMA project–EU (govt): grant, 201711– Horizon 2020 grant €6.3m 4y Liquid biopsies and IMAging for improved cancer care 2017-11-23
Arsanis–New Enterprise Associates: investment, 201711 private placement $20m with 2m shares common stock at $10/share 2017-11-20
Arsanis–SEVERAL: investment, 201711 IPO $46m with 4m+600k shares common stock at $10/share at Nasdaq Global Market 2017-11-20
Ncardia–SEVERAL: investment, 201711 financing round Series B €10.5m led by new investor Épimède 2017-11-17
Viewics–Roche: investment, 201711 acquisition of Viewics Inc by Roche 2017-11-17
High-Tech Gründerfonds–EWE: investment, 201711 € 7-figure investment in HTGF III fund by EWE AG 2017-11-16
Laboratoires Réunis–bio.logis: genetic software, 201711 supply use of bio.logis GIMS by Laboratoires Réunis 2017-11-16
United States (govt)–Molecular Health: drug safety software, 201711–202210 extension collab with CDER for additional 5 years 2017-11-16
Roche–Arvinas: protein degradation drugs, 201711– strategic license expansion for PROTAC technology to Genentech 2017-11-15
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al 2017-11-15
Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195 2017-11-14
Scipio Bioscience–BPCE: investment, 201711 seed financing round totalling €1.2m from Seventure Partners Quadrivium 1 Seed Fund + HTGF 2017-11-14
Scipio Bioscience–High-Tech Gründerfonds: investment, 201711 seed financing round totalling €1.2m from Quadrivium 1 Seed Fund + HTGF 2017-11-14
Scipio Bioscience–SEVERAL: investment, 201711 seed financing round €1.2m from Seventure Partners Quadrivium 1 Seed Fund + HTGF 2017-11-14
Caris Life Sciences–Qiagen: lab automation equipment, 201711 supply QIAsymphony system to Caris Life Sciences 2017-11-13
CRISPR Therapeutics–CureVac: mRNA technology, 201711– collab + license using RNArt techn to develop in-vivo gene-editing programs in liver diseases 2017-11-13
InflaRx–SEVERAL: investment, 201711 IPO $100m w 6.667m common shares at $15/share at Nasdaq Global Select Market 2017-11-10
Ono Pharmaceutical–Neurimmune: drug discovery services, 201711– collab finding mABs against target in neurodegenerative disease using RTM technology 2017-11-09
Boehringer–MiNA Therapeutics: RNAa drugs, 201711– collab up to €307m plus royalties developm of RNAa drugs for fibrotic liver diseases incl NASH 2017-11-08
MiNA Therapeutics–MacDougall Biomedical Communications: public relations, 201711 service existent by MacDougall 2017-11-08
NousCom–5AM Ventures: investment, 201711 financing round Series B totalling €42m incl new + co-investor 5AM Ventures 2017-11-06
NousCom–Abingworth: investment, 201711 financing round Series B totalling €42m incl new + lead investor Abingworth 2017-11-06
NousCom–Huntsworth: public relations, 201711 service existent by Citigate Dewe Rogerson 2017-11-06
NousCom–Life Sciences Partners: investment, 201711 financing round Series B totalling €42m incl returning co-investor LSP 2017-11-06
NousCom–SEVERAL: investment, 201711 financing round Series B €42m led by new investor Abingworth + incl 5AM Ventures + LSP + Versant Ventures 2017-11-06
NousCom–Versant Ventures: investment, 201711 financing round Series B totalling €42m incl returning co-investor Versant Ventures 2017-11-06
Boehringer–Dicerna Pharmaceuticals: RNAi drugs, 201711– collab up to $201m plus royalties developm of RNAi drugs for chronic liver diseases incl NASH 2017-11-02
Evolva–SEVERAL: investment, 201710 capital increase CHF21.1m private placement to Pictet Asset Management + Cologny Advisors at CHF0.31/share 2017-11-02
Evolva–SEVERAL: investment, 201710 capital increase CHF65m discounted right offering 2017-11-02
Topas Therapeutics–Boehringer: investment, 201711 extension of financing round Series A to €18m with €4m investment from BIVF 2017-11-02
Bluebird Bio–Merck (DE): contract manufacturing, 201711– collab long-term commercial manufacturing of lentiviral vector across all Bluebird programs 2017-11-01
Charles River–Caprotec: CCMS technology, 2017 acquisition of CCMS IP + technology of Caprotec by Charles River 2017-11-01
Ada Health–SEVERAL: investment, financing round €40m led by Access Industries (Len Blavatnik) 2017-10-31
BioGeneration Ventures–SEVERAL: investment, 201710 final closing of BGV III with €82m incl new investors BMS + JnJ + Schroder Adveq + MAN Pension 2017-10-31
Blue Ocean Nova–Endress+Hauser: investment, 201710 acquisition €na of Blue Ocean Nova AG 2017-10-31
Advanced Accelerator Applications–Novartis: investment, 201710–201801 cash tender offer $3.9b with $41/ordinary share 2017-10-30
Boehringer–Hospital Corp of America: clinical research, 201710– collab expansion clinical developm combi cancer treatments w Sarah Cannon 2017-10-30
Daiichi Sankyo–Glycotope: antibody-drug conjugates, 201710– option agreem €na for license + collab using Daiichi ADC technology with PankoMab-GEX 2017-10-30
Charles River–InSphero: preclinical cancer models, 201710– collab developm 3D InSight PDX Microtissues for iv oncology services 2017-10-26
Heidelberg ImmunoTherapeutics–Akampion: public relations, 201710 service existent by Akampion 2017-10-26
Phenex–Akampion: public relations, 201710 service existent by Akampion 2017-10-26
next pagenext page 1 2 3 ... 8 9 10 ... 54 55 56  next pagenext page



Advertisement

Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top